Clinical trials: Cutaneous Melanoma, Stage III
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Ipilimumab and Local Radiation for Selected Solid Tumors
This pilot phase 1-2 trial studies the side effects and best of dose ipilimumab when given together with local radiation therapy and to see how well it works in treating patients with recurrent melanoma, non-Hodgkin lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01769222
- Testing
- Ipilimumab, Radiation therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Stanford University
Adult Solid Tumor, Adenocarcinoma of the Colon
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
RATIONALE: PD 0332991 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well PD 0332991 works in treating patients with…
- Conditions
- Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor
- Trial name
- NCT01037790
- Testing
- PD-0332991
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Recurrent Melanoma, Stage III Skin Melanoma
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
This phase II trial is studying how well MEK inhibitor AZD6244 works in treating patients with stage III or stage IV melanoma. MEK inhibitor AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for…
- Conditions
- Recurrent Melanoma, Stage III Skin Melanoma, Stage IV Skin Melanoma
- Trial name
- NCT00866177
- Testing
- Laboratory Biomarker Analysis, Selumetinib
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Melanoma, Stage IIIB Skin Melanoma
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
This phase II trial is studying how well giving temsirolimus together with bevacizumab works in treating patients with stage III or stage IV malignant melanoma.
- Conditions
- Recurrent Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
- Trial name
- Mel47 (NCT00397982)
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
This was a Phase 2, open-label study of the NY-ESO-1 ISCOMATRIX® (ISCOM) vaccine administered as an intramuscular injection given every 4 weeks to subjects with measurable advanced malignant melanoma.
- Trial name
- NCT00518206
- Testing
- NY-ESO-1 ISCOMATRIX® vaccine, Cyclophosphamide
- Where
- 2 sites in Australia
- Volunteers
- 46 people
- Sponsor
- Ludwig Institute for Cancer Research
Melanoma
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
This study aims to determine which of 3 drug combinations best reduces the size of tumour prior to surgery for advanced melanoma and prevents the recurrence of melanoma after surgery.
- Trial name
- Neo Trio (NCT02858921)
- Testing
- Dabrafenib, Trametinib, Pembrolizumab
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Melanoma Institute Australia
Melanoma
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients who have undergone surgery.
- Trial name
- MAVIS (NCT01546571)
- Testing
- POL-103A, POL-103A without API
- Where
- 65 sites in United States, Canada
- Volunteers
- 504 people
- Sponsor
- Polynoma LLC
ALK Fusion Protein Expression, BRAF wt Allele
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work in treating patients with BRAF/NRAS wild-type stage III-IV melanoma.
- Conditions
- ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma, MET Fusion Gene Positive
- Trial name
- NCT02587650
- Testing
- Capmatinib, Ceritinib, Entrectinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, San Francisco
Melanoma (Skin)
Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma. PURPOSE: This phase II trial is studying how well riluzole works in treating patients with stage III or stage IV…
- Trial name
- NCT00866840
- Testing
- riluzole
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Rutgers, The State University of New Jersey
Melanoma
Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
Evaluate the antitumor activity of hu14.18-IL2 in the minimal residual disease setting. Evaluate the time to recurrence and overall survival of patients treated with hu14.18-IL2.
- Trial name
- NCT00590824
- Testing
- hu14.18-IL2
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Wisconsin, Madison
Melanoma, Skin Cancer
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
The purpose of this study is to find out if an investigational drug called panobinostat can be given safely with another drug called ipilimumab.
- Trial name
- NCT02032810
- Testing
- Panobinostat, Ipilimumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
This was a two-arm, double-blinded, randomized, Phase III study comparing dabrafenib and trametinib combination therapy to dabrafenib administered with a placebo (dabrafenib monotherapy).
- Trial name
- NCT01584648
- Testing
- Dabrafenib, Trametinib
- Where
- 121 sites in United States, Argentina and 12 more
- Volunteers
- 423 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
This is a phase 2, single arm, open label, adaptive design study to determine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab.
- Trial name
- SPOTLIGHT203 (NCT04570332)
- Testing
- BO-112 plus pembrolizumab, Tissue Biopsies
- Where
- 19 sites in France, Spain
- Volunteers
- 42 people
- Sponsor
- Highlight Therapeutics
Melanoma
A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
This study is for patients with advanced stage III or stage IV melanoma not adequately treated by surgery who have progressed after treatment with nivolumab or pembrolizumab.
- Trial name
- NCT02796352
- Testing
- High dose bolus interleukin-2 (HD IL2)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ahmad Tarhini
Melanoma (Skin)
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to and kill tumor cells. Colony-stimulating factors such as GM-CSF may increase the number of immune cells found in the bone marrow or…
- Trial name
- NCT00003222
- Testing
- aldesleukin, gp100 antigen, incomplete Freund's adjuvant
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Virginia
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine versus stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm
- Trial name
- NCT04588246
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 81 sites in United States, Canada and 1 more
- Volunteers
- 19 people
- Sponsor
- NRG Oncology
Unresectable Stage III, Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
The purpose of this study is to assess the objective response rate of lenvatinib in previously treated participants with American Joint Committee on Cancer (AJCC) unresectable Stage III or Stage IV melanoma and disease…
- Trial name
- NCT01136967
- Testing
- Lenvatinib
- Where
- 95 sites in United States, Australia and 2 more
- Volunteers
- 182 people
- Sponsor
- Eisai Inc.
Melanoma
Phase IIB TL + YCWP + DC in Melanoma
The majority of melanoma vaccines tested to date have been antigen-specific vaccines targeting melanoma-specific or associated antigens and utilizing a variety of delivery systems and immune-adjuvants.
- Trial name
- NCT02301611
- Testing
- TLPLDC
- Where
- 18 sites in United States
- Volunteers
- 187 people
- Sponsor
- Elios Therapeutics, LLC
Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
This randomized phase II trial studies how well giving pembrolizumab with standard chemotherapy, tumor infiltrating lymphocytes (TIL), and aldesleukin works in treating patients with melanoma that has spread to other areas of the…
- Conditions
- Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Trial name
- NCT02500576
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma (Skin)
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with locally advanced or…
- Trial name
- NCT00700882
- Testing
- dasatinib
- Where
- 153 sites in United States
- Volunteers
- 81 people
- Sponsor
- Eastern Cooperative Oncology Group